Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-β1-adrenergic receptor antibody neutralization and of immune parameters

    loading  Checking for direct PDF access through Ovid


AimsA novel concept for the treatment of heart failure is the neutralization of antibodies against the β1-adrenergic receptor (anti-β1AR-ab). In a rat model of autoimmune cardiomyopathy, the cyclic peptide COR-1 (given i.v. once monthly) neutralized anti-β1AR-abs and prevented anti-β1AR-ab-induced myocardial damage, and completely reverted cardiac dysfunction over 3–6 months.Methods and resultsA clinical phase I trial was designed as a single-blinded, placebo-controlled study. Fifty human volunteers received COR-1 or matching placebo as a single i.v. administration with ascending doses (10–240 mg). Primary endpoints were safety and tolerability, while the pharmacokinetic profile of COR-1 was assessed as a secondary endpoint. All five investigated dose groups were well tolerated; no drug-related side effects occurred. Pharmacokinetics revealed a favourable profile with an almost complete plasma clearance within 60 min after administration. Pharmacodynamic investigation showed dose-dependent efficacy with almost complete scavenging of pathological anti-β1AR-abs ex vivo at the two highest doses. No anti-COR-1 autoantibodies occurred. No other effects on the immune system (such as an increase of crucial cytokines) were observed up to 43 days after drug administration, nor upon incubation of anti-β1AR-ab-positive patient blood samples with COR-1 ex vivo.ConclusionsCOR-1 was shown to be safe after i.v. administration in vivo; no relevant side effects occurred. Efficacy was estimated from ex vivo investigation of the potency to neutralize specific anti-β1-AR-abs. Trial registration: NCT 01043146, Eudra CT 2008-007745-31.

    loading  Loading Related Articles